Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 39.31B P/E 12.96 EPS this Y 5.20% Ern Qtrly Grth -54.60%
Income 1.16B Forward P/E 16.14 EPS next Y 13.60% 50D Avg Chg -6.00%
Sales 9.84B PEG 4.57 EPS past 5Y -18.06% 200D Avg Chg -5.00%
Dividend N/A Price/Book 2.72 EPS next 5Y 2.80% 52W High Chg -15.00%
Recommedations 2.10 Quick Ratio 1.04 Shares Outstanding 145.36M 52W Low Chg 40.00%
Insider Own 0.69% ROA 4.58% Shares Float 144.82M Beta -0.01
Inst Own 92.98% ROE 8.24% Shares Shorted/Prior 3.55M/2.80M Price 271.56
Gross Margin 74.24% Profit Margin 11.81% Avg. Volume 1,141,158 Target Price 300.93
Oper. Margin 19.32% Earnings Date Apr 24 Volume 1,291,128 Change 0.84%
About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc. News
04/12/24 Biogen Is Suffering From Doubts About the Future
04/11/24 Is Eli Lilly Stock A Buy Or A Sell After FDA Delays Its Alzheimer's Drug Decision?
04/01/24 Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know
03/31/24 Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
03/28/24 Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
03/26/24 CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
03/25/24 Biogen Inc. (BIIB) Dips More Than Broader Market: What You Should Know
03/25/24 Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test
03/22/24 UPDATE 3-EU regulator delays decision on Eisai-Biogen Alzheimer's drug
03/21/24 Hedge Funds and Insiders Are Buying These 10 Stocks
03/21/24 Biogen, Moderna, and 6 More Healthcare Stocks That Wall Street Thinks Have Upside
03/18/24 Here's Why Biogen Inc. (BIIB) Gained But Lagged the Market Today
03/18/24 25 Most Stressed Cities in the United States
03/14/24 Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?
03/12/24 Biogen Inc. (BIIB) Stock Falls Amid Market Uptick: What Investors Need to Know
03/11/24 20 Highest Paying Countries for Biotechnology
03/08/24 FDA delays approval deadline for Eli Lilly's Alzheimer's drug
03/08/24 FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer's drug
03/08/24 Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision
03/08/24 Eli Lilly Alzheimer’s Drug Delayed as FDA Plans Advisory Panel Meeting
BIIB Chatroom

User Image Tomppa Posted - 21 minutes ago

$BIIB one year to direction of zero, what is the hope for turn around ?

User Image Game_Day Posted - 2 days ago

Latest FREE alerts ⭐️⭐️ $TPET 300%+ 🌮 $ZPTA 40%+ $ELYM 20%+ $BIIB 10%+ ELYM 3 bullflags Friday

User Image Jtex07 Posted - 3 days ago

@umiak1 @coreholder @pfelinepfrenzy1990 good explanation/definitions for newbies and uneducated that needed to hear that. Been around a long time and I’m usually in industrials but Pfizer has been on my watchlist for a long time so I bought in. Mows a great time to do it and not even a swing trade,…. RSV vaccines and the pipeline behind it are gold. I’ll collect a 6% divvy while I wait for this to go boom soon enough. Now is loading zone time. Especially with the triple bottom! because of their pipeline, I see more potential since it’s already down and showing support then other stocks, such as $biib at least for the moment!

User Image Jtex07 Posted - 3 days ago

@Chartist0_0 funny how I see you on other stocks I’m interested in. Great minds think alike they say! I’m in on $PFE but holding off for a bit on $BIIB. It reminds me of $AAL and $UAL in that they will have great 2026’s so I will buy them late this year unless something else comes up. Pfizer just looks closer to be ready to jump with drug pipeline imo. Do you see something in the charts I don’t? I picked Pfizer because of a triple bottom

User Image grinchspan Posted - 3 days ago

$BIIB under 200. Further to fall.

User Image Fixaleg Posted - 3 days ago

@STOCKPICKERTRADER painful action in the group for sure, but added shares on $PFE and started positions in $BMY $BIIB $BIDU $BTI

User Image DrBig Posted - 4 days ago

$BIIB market hates everybody today

User Image Market_Max Posted - 4 days ago

@jjl013 lol… if you really think it falling back to $22.xx matters to any true long here, then you are new in town… it doesn’t matter where it ends today, or tomorrow. Why don’t you go take a look at what’s gone on with $BIIB and other Neuro-type companies…. SAVA will live or die by its own fundamentals… not the stuff going on now fella!

User Image pfh_investing Posted - 4 days ago

$XBI market really hates biotech today lol $MRNA $PFE $BIIB

User Image STOCKPICKERTRADER Posted - 4 days ago

$PFE markets resetting and bio/pharma remains the dog to kick for some reason - $XBI $BIIB $AMGN $BMY $PFE and plenty of others in the group. Watching to add more shares on a few today as markets rotate crops into undervalued stocks with some seasonal trends and other factors favoring this group in the months ahead.

User Image erevnon Posted - 4 days ago

B of A Securities maintains Biogen $BIIB at Neutral and lowers the price target from $280 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image Giletjaune Posted - 4 days ago

$BIIB Ten years horizontal bottomline......

User Image WorkisWorthit Posted - 5 days ago

$BIIB trash $SAVA All Day

User Image erevnon Posted - 5 days ago

JP Morgan maintains Biogen $BIIB at Neutral and lowers the price target from $270 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image RainbowTrump Posted - 5 days ago

$BIIB what do these companies even make money off of? $GILD Anything in the pipeline that’s noteworthy?

User Image DrBig Posted - 5 days ago

$BIIB pos

User Image buytheDip1000 Posted - 6 days ago

$BIIB 200.86

User Image ravi9 Posted - 6 days ago

$BIIB 200 shares in

User Image JohnnyAM_D Posted - 6 days ago

$BIIB picked up 1000 shares

User Image WorkisWorthit Posted - 1 week ago

$BIIB short $BIIB $SAVA Long

User Image WinYuZhao Posted - 1 week ago

$BIIB this shit only goes down

User Image Tshanky_ Posted - 1 week ago

$NRSN no longer partnered with $BIIB . Data May be delayed til q3 now. ALS drug seems like it’s special but a lot of tough news today

User Image Mikeqb20 Posted - 1 week ago

$NRSN #CureALS NEXT 10X BANGER!! Partner is $BIIB NO ALS DRUGS ON MARKET WITH $AMLX FAILURE $NRSN NEXT 10X BANGER $VKTX and $CRBP BOTH 10X PLAYS @RealAvidTrader @jacksparo

User Image Mikeqb20 Posted - 1 week ago

$NRSN @Tshanky_ ON FIRE!!!! #CureALS 10X BANGER FROM HERE WITH GOOD $BIIB NEWS

User Image Mikeqb20 Posted - 1 week ago

$NRSN GOING to be my next 10X BANGER with good news with $BIIB Told ya on $VKTX and $CRBP BOTH 10X BANGERS! Next up is $NRSN #CureALS

User Image DrBig Posted - 1 week ago

$BIIB time to bounce

User Image erevnon Posted - 1 week ago

Barclays maintains Biogen $BIIB at Equal-Weight and lowers the price target from $230 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image Game_Day Posted - 1 week ago

Latest alerts 🔥 Options $COST 🔥 30%+ $BIIB ⭐️ 5% Stocks $IGC ⭐️ 20% $TCON ⭐️ 15% SIGNATURE ALERTS $ZTS 🏆 60%+

User Image kiwiSurfer Posted - 1 week ago

@Herr_Chicken @WNTCT recall that $VYGR cut a Big Deal in January 24 with upfront and residuals for a far INFERIOR capsid (100M upfront). I see a STAC-BBB Deal obviate all this speculation and render it irrelevant. $LLY $BIIB or another Big Pharma will see the potential CNS Goldmine in plain view.

User Image Chartist0_0 Posted - 1 week ago

$BIIB new purchase. Haven’t bought this name in years.

Analyst Ratings
B of A Securities Neutral Apr 12, 24
JP Morgan Neutral Apr 11, 24
Barclays Equal-Weight Apr 4, 24
Truist Securities Buy Mar 25, 24
RBC Capital Outperform Mar 5, 24
Mizuho Buy Feb 22, 24
Cantor Fitzgerald Overweight Feb 20, 24
Canaccord Genuity Buy Feb 20, 24
UBS Neutral Feb 16, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Singhal Priya Head of Development Head of Development Feb 01 Sell 245.93 634 155,920 4,097 02/05/24
Singhal Priya Head of Development Head of Development Feb 01 Option 0 1,828 5,292 02/05/24
Singhal Priya Head of Development Head of Development Dec 08 Sell 248 110 27,280 3,464 12/12/23
Singhal Priya Head of Development Head of Development Dec 08 Option 0 426 3,780 12/12/23
Singhal Priya Head of Development Head of Development Sep 01 Sell 269.43 431 116,124 3,354 09/06/23
Singhal Priya Head of Development Head of Development Sep 01 Option 0 1,668 4,592 09/06/23
Gregory Ginger EVP, Human Resources EVP, Human Resources Apr 28 Sell 300.00 2,681 804,300 8,483 05/02/23
Singhal Priya Head of Development Head of Development Apr 04 Sell 277.11 91 25,217 2,843 04/06/23
Singhal Priya Head of Development Head of Development Mar 28 Sell 270.06 568 153,394 2,842 03/30/23
Gregory Ginger EVP, Human Resources EVP, Human Resources Nov 14 Sell 300.11 5,610 1,683,617 5,711 12/12/22
ALEXANDER SUSAN H EVP Chief Legal Off.. EVP Chief Legal Off & Corp Sec Oct 27 Sell 280.70 5,532 1,552,832 39,396 10/28/22